PCA
PLRX icon

Peddock Capital Advisors’s Pliant Therapeutics PLRX Stock Holding History

Peddock Capital Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-92
Closed -$2K – 253
2020
Q4 		$2K Buy
+92
New +$2.31K ﹤0.01% 262

Other funds holding PLRX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Peddock Capital Advisors's PLRX Position: Q1 2021 in Review

Peddock Capital Advisors sold out of Pliant Therapeutics (PLRX) in Q1 2021, closing a stake of 92 shares — an estimated $2K sold.

Peddock Capital Advisors first reported a position in PLRX in Q4 2020 and held it in 1 quarter. The position peaked at $2K in Q4 2020. 76 funds tracked by Wall St. Rank hold PLRX as of Q1 2021.

  • Peddock Capital Advisors reported no remaining Pliant Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Peddock Capital Advisors sold 92 Pliant Therapeutics shares in Q1 2021, an estimated $2K.
  • Peddock Capital Advisors first reported a position in Pliant Therapeutics in Q4 2020 and held it in 1 quarter.
  • Peddock Capital Advisors's Pliant Therapeutics position peaked at $2K in Q4 2020.
  • 76 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2021.

Based on Peddock Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.